What's new

Human medicines European public assessment report (EPAR): Lunsumio, mosunetuzumab, Date of authorisation: 03/06/2022, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Lunsumio, mosunetuzumab, Date of authorisation: 03/06/2022, Revision: 6, Status: Authorised

May 6, 2025 - 16:13
 0
Human medicines European public assessment report (EPAR): Lunsumio, mosunetuzumab, Date of authorisation: 03/06/2022, Revision: 6, Status: Authorised
Human medicines European public assessment report (EPAR): Lunsumio, mosunetuzumab, Date of authorisation: 03/06/2022, Revision: 6, Status: Authorised
Read More

Tags:

Previous Article

Mullen subsidiary, Bollinger Motors, delivers B4 commercial electric truck to NY...

Next Article

Human medicines European public assessment report (EPAR): Xydalba, dalbavancin, ...

Related Posts

Human medicines European public assessment report (EPAR): Iqirvo, Elafibranor, Date of authorisation: 19/09/2024, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR...

May 6, 2025  0

Human medicines European public assessment report (EPAR): Lenvima, lenvatinib, Date of authorisation: 28/05/2015, Revision: 26, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 22, 2025  0

Draft ICH Q1 guideline on stability testing of drug sub...

Apr 30, 2025  0